What Gilead Sciences, Inc. reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 882095 · Filed Aug 3, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 16.7M |
| ±0% |
| $500.2M |
| 30.3% |
ASMBAssembly Biosciences, Inc. | 5M | +10.5% | $136.8M | 8.3% |
KYTXKyverna Therapeutics, Inc. | 4.1M | ±0% | $36.8M | 2.2% |
XLOXilio Therapeutics, Inc. | 650.4K | ±0% | $6.2M | 0.4% |